Skip to main content
. 2017 Oct 27;7:14275. doi: 10.1038/s41598-017-14290-3

Figure 2.

Figure 2

ACVR2B/Fc treatment prevents muscle fibre atrophy. (A) the lesser fibre diameter of myofibres in the TA and quadriceps of WT and R6/2 mice treated with ACVR2B/Fc or vehicle. Fibre counts were obtained from between 3 and 8 sections per mouse, n = 3 or 4 mice/treatment group. The WT muscle fibre diameters were greater than those for R6/2: quadriceps (F(13,10) = 28.82, p ≤ 0.001), TA (F(15,12) = 10.29, p = 0.008). ACVR2B/Fc treatment increased the fibre diameter in both cases: quadriceps (F(13,10) = 92.8, p ≤ 0.001) and TA (F(15,12) = 12.73, p = 0.004). ACVR2B/Fc treatment increased fibre diameter in the quadriceps (p < 0.001) and the TA (p = 0.061) of R6/2 mice. Representative traces from individual mice are depicted. Statistical analysis was two-way ANOVA with post-hoc Bonferroni correction.